Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon
Søg Study Connect
  • NCT07063745

Not Yet Recruiting

A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion - CA240-0029

Opdateret: 3 juli, 2025   |   ClinicalTrials.gov

Udskriftsvenligt sammendrag

OVERVEJER DU DETTE FORSØG?
Udskriv denne side og forsøgsvejledningen som en hjælp til at tale med din læge.
Brug vejledningen til forsøgsdeltagere for at finde rundt i processen for deltagelse i et klinisk forsøg. Forstå de vigtigste faktorer, der skal overvejes, før du beslutter dig, og find spørgsmål, du kan stille dit sundhedsteam.
Udskriv denne side CA240-0029
Hente vejledningen til forsøgsdeltagere

VÆLG SPROG

Forsøgsdetaljer

  • Phase 2/Phase 3

    Fase

  • Køn

  • 18+

    Aldersinterval

  • 77

    Beliggenhed(er)

  • Not Yet Recruiting

Behandlingsmuligheder

Forsøgsgrene
TILDELT INTERVENTION
Active Comparator: Arm A: BMS-986504 + Pembrolizumab + Chemotherapy
Drug: BMS-986504, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Paclitaxel, Nab-paclitaxel
Active Comparator: Arm B: BMS-986504 + Pembrolizumab + Chemotherapy
Drug: BMS-986504, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Paclitaxel, Nab-paclitaxel
Placebo Comparator: Arm C: Placebo + Pembrolizumab + Chemotherapy
Drug: Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Paclitaxel, Nab-paclitaxel Other: Placebo
Placebo Comparator: Arm D: Placebo + Pembrolizumab + Chemotherapy
Drug: Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Paclitaxel, Nab-paclitaxel Other: Placebo
Active Comparator: Arm E: BMS-986504 + Pembrolizumab + Chemotherapy
Drug: BMS-986504, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Paclitaxel, Nab-paclitaxel
Placebo Comparator: Arm F: Placebo + Pembrolizumab + Chemotherapy
Drug: Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Paclitaxel, Nab-paclitaxel Other: Placebo

Primære egnethedskriterier

Inclusion Criteria - Participants must have Metastatic (Stage IV or recurrent) non-small cell lung cancer (NSCLC) (as defined by the American Joint Committee on Cancer, Ninth Edition) with no prior systemic anti-cancer therapy for metastatic disease. - Participants must have histologically confirmed diagnosis of NSCLC and homozygous methylthioadenosine phosphorylase (MTAP) deletion or MTAP loss. - Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. - Participants must have at least 1 measurable lesion as per RECIST v1.1. Exclusion Criteria - Nonsquamous participants must not have documented targetable oncogenic mutation or actionable genetic alterations (AGAs) for which there is a standard of care (SoC) available as first-line (1L) therapy. - Participants must not have symptomatic brain metastases or spinal cord compression. - Participants must not have any prior systemic therapy (chemotherapy, immunotherapy, targeted therapy, or biological therapy) for metastatic non-small cell lung cancer (mNSCLC). Note: One cycle of SoC treatment prior to randomization will be allowed for participants who require immediate treatment if clinically indicated. - Participants must not have any known or suspected impairment of gastrointestinal function that may prohibit the ability to absorb or swallow an oral medication without chewing or crushing. - Other protocol-defined Inclusion/Exclusion criteria apply.

Hvis du vil rapportere en bivirkning, kan du indberette direkte til Lægemiddelstyrelsen via hjemmesiden www.meldenbivirkning.dk
Vi anbefaler at du også kontakter BMS for at rapportere bivirkninger.
Bivirkninger og andre rapporterbare begivenheder er defineret her
Rapporter bivirkninger eller klager over produktkvalitet: Medicinsk information

466-DK-2200001